Research suggests that white willow bark and its primary active constituent, salicin, may offer meaningful relief for headache and migraine symptoms, with available studies generally pointing in a supportive direction. The evidence base includes a meta-analysis examining white willow bark combined with feverfew that reported reductions in migraine attack frequency, intensity, and duration, as well as a double-blind placebo-controlled trial finding that topical salicin reduced headache duration and the need for additional pain medication compared to placebo. A mechanistic paper also situates these findings within a broader framework of how salicin may act on neuronal pathways relevant to pain. That said, the overall body of evidence remains limited in size, some studies examine willow bark in combination with other ingredients rather than in isolation, and further independent replication would be needed before firm conclusions can be drawn.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Tanacetum parthenium and Salix alba (Mig-RL) combination in migraine prophyla... | Meta-analysis | 2006 | Supports | 97 |
| Anticephalgic photoprotective premedicated mask. A report of a successful dou... | RCT | 1998 | Supports | 90 |
| Salicin from Willow Bark can Modulate Neurite Outgrowth in Human Neuroblastom... | Other | 2015 | Supports | 85 |